查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2132511

迷幻藥市場規模、佔有率和趨勢分析報告：按藥物類型、適應症、給藥途徑、分銷管道、地區和細分市場預測（2026-2033 年）

Psychedelic Drugs Market Size, Share & Trends Analysis Report By Drug Type (Entactogens, Dissociatives), By Indication, By Route of Administration (Oral, Parenteral), By Distribution Channel, By Region, And Segment Forecasts, 2026 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

迷幻藥市場概述

全球迷幻藥市場預計到 2025 年價值 41 億美元，到 2026 年成長到 47 億美元，到 2033 年擴大到 117 億美元，2026 年至 2033 年的複合年成長率為 14.1%。

北美市場處於領先地位，預計到 2025 年將佔銷售額的 41.2%。該市場是一個新興的製藥市場，專注於開發用於治療精神疾病和物質使用障礙的迷幻化合物。

目前臨床試驗中研究的主要物質包括裸蓋菇素、3,4-甲基安非他命（MDMA）、N,N-二甲基色胺（DMT）和伊博加鹼。研究主要集中在難治性憂鬱症、重度憂鬱症、創傷後壓力症候群（PTSD）和酒精使用障礙。持續進行的臨床試驗、生物技術和製藥公司的投資以及針對現有療法療效不佳患者的治療研究為市場提供了支持。然而，由於大多數迷幻藥物仍處於臨床開發階段，目前的市場供應有限。開發過程也涉及管制物質的相關法規、專門的給藥方案、病患監測和心理支持。這些要求可能會增加開發和治療成本，進而影響迷幻藥物療法的廣泛應用。缺乏長期安全性數據、監管的不確定性以及對訓練有素的醫療保健專業人員的需求仍然是影響市場發展的主要因素。

目錄

第1章：調查方法和範圍

第2章執行摘要

第3章 迷幻藥市場：變數、趨勢與範圍

  • 市場譜系展望
  • 市場動態
  • 商業環境分析

第4章：迷幻藥市場：按藥物類型分類的商業分析

  • 按藥物類型分類的市場佔有率，2025 年和 2033 年
  • 市場規模、預測與趨勢分析：按藥物類型分類，2021-2033 年
  • 經典迷幻藥
  • 腸桿菌
  • 分離性藥物
  • 其他

第5章：迷幻藥市場：依適應症分類的商業分析

  • 按適應症分類的市場佔有率，2025 年和 2033 年
  • 市場規模、預測與趨勢分析：按適應症分類，2021-2033 年
  • 憂鬱症
  • 創傷和壓力相關疾病
  • 焦慮症
  • 物質使用障礙
  • 強迫症及相關疾病
  • 生命末期的心理困擾
  • 其他

第6章：迷幻藥市場：依給藥途徑進行商業分析

  • 按行政途徑分類的市場佔有率，2025 年和 2033 年
  • 市場規模、預測與趨勢分析：按給藥途徑分類，2021-2033 年
  • 口服
  • 鼻內給藥
  • 腸外
  • 其他

第7章：迷幻藥市場：依通路進行業務分析

  • 按分銷管道分類的市場佔有率，2025 年和 2033 年
  • 市場規模、預測與趨勢分析：按分銷管道分類，2021-2033 年
  • 醫院藥房
  • 專科藥房
  • 零售藥房
  • 其他

第8章：迷幻藥市場：區域估算與趨勢分析

  • 2025年及2033年區域市佔率分析
  • 區域市場概覽
  • 市場規模、預測與趨勢分析，2021-2033年
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • UAE
    • 科威特

第9章 競爭情勢

  • 參與企業概況
  • 公司市場分析
  • 公司分類
  • 策略規劃
  • 公司簡介列表
    • Compass Pathways plc.
    • Definium Therapeutics, Inc.
    • Helus Pharma Inc.
    • GH Research plc.
    • Johnson & Johnson
    • Eli Lilly and Company
    • Otsuka Pharmaceutical Co., Ltd.
    • AbbVie Inc.
    • Incannex Healthcare Limited
    • Optimi Health Corp.
Product Code: GVR-4-68040-171-0

Psychedelic Drugs Market Summary

The global psychedelic drugs market size was valued at USD 4.1 billion in 2025 and is projected to grow from USD 4.7 billion in 2026 to USD 11.7 billion by 2033, at a CAGR of 14.1% from 2026 to 2033. North America dominated the market, accounting for revenue share of 41.2% in 2025. The market is an emerging pharmaceutical market focused on the development of psychedelic compounds for the treatment of mental health and substance use disorders.

Key substances under clinical investigation include psilocybin, 3,4-methylenedioxymethamphetamine (MDMA), N,N-dimethyltryptamine (DMT), and ibogaine. Research is primarily focused on treatment-resistant depression, major depressive disorder, post-traumatic stress disorder, and alcohol use disorder. The market is supported by ongoing clinical trials, investments by biotechnology and pharmaceutical companies, and research into treatment options for patients with inadequate response to existing therapies. However, most psychedelic drugs remain in clinical development, limiting their current commercial availability. Development also involves controlled-substance regulations, specialized administration protocols, patient monitoring, and psychological support. These requirements can increase development and treatment costs and may affect the adoption of psychedelic-based therapies. Limited long-term safety data, regulatory uncertainty, and the need for trained healthcare professionals remain key factors affecting market development.

Global Psychedelic Drugs Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global psychedelic drugs market report based on drug type, indication, route of administration, distribution channel, and region:

  • Drug Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Classical Psychedelics
  • Entactogens
  • Dissociatives
  • Others
  • Indication Outlook (Revenue, USD Million, 2021 - 2033)
  • Depressive Disorders
  • Trauma- and Stressor-Related Disorders
  • Anxiety Disorders
  • Substance Use Disorders
  • Obsessive-Compulsive and Related Disorders
  • End-of-Life Psychological Distress
  • Others
  • Route of Administration Outlook (Revenue, USD Million, 2021 - 2033)
  • Oral
  • Intranasal
  • Parenteral
  • Others
  • Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)
  • Hospital Pharmacies
  • Specialty Pharmacies
  • Retail Pharmacies
  • Others
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Drug Type
    • 1.2.2. Indication
    • 1.2.3. Route of Administration
    • 1.2.4. Distribution Channel
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Psychedelic Drugs Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis
    • 3.3.3. Pipeline Analysis
    • 3.3.4. Patent Expiry Analysis
    • 3.3.5. Pricing Analysis

Chapter 4. Psychedelic Drugs Market: Drug Type Business Analysis

  • 4.1. Drug Type Market Share, 2025 & 2033
  • 4.2. Drug Type Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Drug Type, 2021 to 2033 (USD Million)
  • 4.4. Classical Psychedelics
    • 4.4.1. Classical Psychedelics Market, 2021 - 2033 (USD Million)
  • 4.5. Entactogens
    • 4.5.1. Entactogens Market, 2021 - 2033 (USD Million)
  • 4.6. Dissociatives
    • 4.6.1. Dissociatives Market, 2021 - 2033 (USD Million)
  • 4.7. Others
    • 4.7.1. Others Market, 2021 - 2033 (USD Million)

Chapter 5. Psychedelic Drugs Market: Indication Business Analysis

  • 5.1. Indication Market Share, 2025 & 2033
  • 5.2. Indication Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Indication, 2021 to 2033 (USD Million)
  • 5.4. Depressive Disorders
    • 5.4.1. Depressive Disorders Market, 2021 - 2033 (USD Million)
  • 5.5. Trauma- and Stressor-Related Disorders
    • 5.5.1. Trauma- and Stressor-Related Disorders Market, 2021 - 2033 (USD Million)
  • 5.6. Anxiety Disorders
    • 5.6.1. Anxiety Disorders Market, 2021 - 2033 (USD Million)
  • 5.7. Substance Use Disorders
    • 5.7.1. Substance Use Disorders Market, 2021 - 2033 (USD Million)
  • 5.8. Obsessive-Compulsive and Related Disorders
    • 5.8.1. Obsessive-Compulsive and Related Disorders Market, 2021 - 2033 (USD Million)
  • 5.9. End-of-Life Psychological Distress
    • 5.9.1. End-of-Life Psychological Distress Market, 2021 - 2033 (USD Million)
  • 5.10. Others
    • 5.10.1. Others Market, 2021 - 2033 (USD Million)

Chapter 6. Psychedelic Drugs Market: Route of Administration Business Analysis

  • 6.1. Route of Administration Market Share, 2025 & 2033
  • 6.2. Route of Administration Segment Dashboard
  • 6.3. Market Size & Forecasts and Trend Analysis, by Route of Administration, 2021 to 2033 (USD Million)
  • 6.4. Oral
    • 6.4.1. Oral Market, 2021 - 2033 (USD Million)
  • 6.5. Intranasal
    • 6.5.1. Intranasal Market, 2021 - 2033 (USD Million)
  • 6.6. Parenteral
    • 6.6.1. Parenteral Market, 2021 - 2033 (USD Million)
  • 6.7. Others
    • 6.7.1. Others Market, 2021 - 2033 (USD Million)

Chapter 7. Psychedelic Drugs Market: Distribution Channel Business Analysis

  • 7.1. Distribution Channel Market Share, 2025 & 2033
  • 7.2. Distribution Channel Segment Dashboard
  • 7.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2021 to 2033 (USD Million)
  • 7.4. Hospital Pharmacies
    • 7.4.1. Hospital Pharmacies Market, 2021 - 2033 (USD Million)
  • 7.5. Specialty Pharmacies
    • 7.5.1. Specialty Pharmacies Market, 2021 - 2033 (USD Million)
  • 7.6. Retail Pharmacies
    • 7.6.1. Retail Pharmacies Market, 2021 - 2033 (USD Million)
  • 7.7. Others
    • 7.7.1. Others Market, 2021 - 2033 (USD Million)

Chapter 8. Psychedelic Drugs Market: Regional Estimates & Trend Analysis

  • 8.1. Regional Market Share Analysis, 2025 & 2033
  • 8.2. Regional Market Dashboard
  • 8.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
  • 8.4. North America
    • 8.4.1. North America Psychedelic Drugs Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)
    • 8.4.2. U.S.
      • 8.4.2.1. Key Country Dynamics
      • 8.4.2.2. Target Disease Prevalence
      • 8.4.2.3. Regulatory Framework
      • 8.4.2.4. Reimbursement Framework
      • 8.4.2.5. U.S.Psychedelic Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.4.3. Canada
      • 8.4.3.1. Key Country Dynamics
      • 8.4.3.2. Target Disease Prevalence
      • 8.4.3.3. Regulatory Framework
      • 8.4.3.4. Reimbursement Framework
      • 8.4.3.5. Canada Psychedelic Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.4.4. Mexico
      • 8.4.4.1. Key Country Dynamics
      • 8.4.4.2. Target Disease Prevalence
      • 8.4.4.3. Regulatory Framework
      • 8.4.4.4. Reimbursement Framework
      • 8.4.4.5. Mexico Psychedelic Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5. Europe
    • 8.5.1. Europe Psychedelic Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.5.2. UK
      • 8.5.2.1. Key Country Dynamics
      • 8.5.2.2. Target Disease Prevalence
      • 8.5.2.3. Regulatory Framework
      • 8.5.2.4. Reimbursement Framework
      • 8.5.2.5. UK Psychedelic Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.5.3. Germany
      • 8.5.3.1. Key Country Dynamics
      • 8.5.3.2. Target Disease Prevalence
      • 8.5.3.3. Regulatory Framework
      • 8.5.3.4. Reimbursement Framework
      • 8.5.3.5. Germany Psychedelic Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.5.4. France
      • 8.5.4.1. Key Country Dynamics
      • 8.5.4.2. Target Disease Prevalence
      • 8.5.4.3. Regulatory Framework
      • 8.5.4.4. Reimbursement Framework
      • 8.5.4.5. France Psychedelic Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.5.5. Italy
      • 8.5.5.1. Key Country Dynamics
      • 8.5.5.2. Target Disease Prevalence
      • 8.5.5.3. Regulatory Framework
      • 8.5.5.4. Reimbursement Framework
      • 8.5.5.5. Italy Psychedelic Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.5.6. Spain
      • 8.5.6.1. Key Country Dynamics
      • 8.5.6.2. Target Disease Prevalence
      • 8.5.6.3. Regulatory Framework
      • 8.5.6.4. Reimbursement Framework
      • 8.5.6.5. Spain Psychedelic Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.5.7. Denmark
      • 8.5.7.1. Key Country Dynamics
      • 8.5.7.2. Target Disease Prevalence
      • 8.5.7.3. Regulatory Framework
      • 8.5.7.4. Reimbursement Framework
      • 8.5.7.5. Denmark Psychedelic Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.5.8. Sweden
      • 8.5.8.1. Key Country Dynamics
      • 8.5.8.2. Target Disease Prevalence
      • 8.5.8.3. Regulatory Framework
      • 8.5.8.4. Reimbursement Framework
      • 8.5.8.5. Sweden Psychedelic Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.5.9. Norway
      • 8.5.9.1. Key Country Dynamics
      • 8.5.9.2. Target Disease Prevalence
      • 8.5.9.3. Regulatory Framework
      • 8.5.9.4. Reimbursement Framework
      • 8.5.9.5. Norway Psychedelic Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6. Asia Pacific
    • 8.6.1. Asia Pacific Psychedelic Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.6.2. Japan
      • 8.6.2.1. Key Country Dynamics
      • 8.6.2.2. Target Disease Prevalence
      • 8.6.2.3. Regulatory Framework
      • 8.6.2.4. Reimbursement Framework
      • 8.6.2.5. Japan Psychedelic Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.6.3. China
      • 8.6.3.1. Key Country Dynamics
      • 8.6.3.2. Target Disease Prevalence
      • 8.6.3.3. Regulatory Framework
      • 8.6.3.4. Reimbursement Framework
      • 8.6.3.5. China Psychedelic Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.6.4. India
      • 8.6.4.1. Key Country Dynamics
      • 8.6.4.2. Target Disease Prevalence
      • 8.6.4.3. Regulatory Framework
      • 8.6.4.4. Reimbursement Framework
      • 8.6.4.5. India Psychedelic Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.6.5. Australia
      • 8.6.5.1. Key Country Dynamics
      • 8.6.5.2. Target Disease Prevalence
      • 8.6.5.3. Regulatory Framework
      • 8.6.5.4. Reimbursement Framework
      • 8.6.5.5. Australia Psychedelic Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.6.6. South Korea
      • 8.6.6.1. Key Country Dynamics
      • 8.6.6.2. Target Disease Prevalence
      • 8.6.6.3. Regulatory Framework
      • 8.6.6.4. Reimbursement Framework
      • 8.6.6.5. South Korea Psychedelic Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.6.7. Thailand
      • 8.6.7.1. Key Country Dynamics
      • 8.6.7.2. Target Disease Prevalence
      • 8.6.7.3. Regulatory Framework
      • 8.6.7.4. Reimbursement Framework
      • 8.6.7.5. Thailand Psychedelic Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7. Latin America
    • 8.7.1. Latin America Psychedelic Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.7.2. Brazil
      • 8.7.2.1. Key Country Dynamics
      • 8.7.2.2. Target Disease Prevalence
      • 8.7.2.3. Regulatory Framework
      • 8.7.2.4. Reimbursement Framework
      • 8.7.2.5. Brazil Psychedelic Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.7.3. Argentina
      • 8.7.3.1. Key Country Dynamics
      • 8.7.3.2. Target Disease Prevalence
      • 8.7.3.3. Regulatory Framework
      • 8.7.3.4. Reimbursement Framework
      • 8.7.3.5. Argentina Psychedelic Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.8. Middle East and Africa
    • 8.8.1. Middle East and Africa Psychedelic Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.8.2. South Africa
      • 8.8.2.1. Key Country Dynamics
      • 8.8.2.2. Target Disease Prevalence
      • 8.8.2.3. Regulatory Framework
      • 8.8.2.4. Reimbursement Framework
      • 8.8.2.5. South Africa Psychedelic Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.8.3. Saudi Arabia
      • 8.8.3.1. Key Country Dynamics
      • 8.8.3.2. Target Disease Prevalence
      • 8.8.3.3. Regulatory Framework
      • 8.8.3.4. Reimbursement Framework
      • 8.8.3.5. Saudi Arabia Psychedelic Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.8.4. UAE
      • 8.8.4.1. Key Country Dynamics
      • 8.8.4.2. Target Disease Prevalence
      • 8.8.4.3. Regulatory Framework
      • 8.8.4.4. Reimbursement Framework
      • 8.8.4.5. UAE Psychedelic Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.8.5. Kuwait
      • 8.8.5.1. Key Country Dynamics
      • 8.8.5.2. Target Disease Prevalence
      • 8.8.5.3. Regulatory Framework
      • 8.8.5.4. Reimbursement Framework
      • 8.8.5.5. Kuwait Psychedelic Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Participant Overview
  • 9.2. Company Market Position Analysis
  • 9.3. Company Categorization
  • 9.4. Strategy Mapping
  • 9.5. Company Profiles/Listing
    • 9.5.1. Compass Pathways plc.
      • 9.5.1.1. Overview
      • 9.5.1.2. Financial Performance
      • 9.5.1.3. Product Benchmarking
      • 9.5.1.4. Strategic Initiatives
    • 9.5.2. Definium Therapeutics, Inc.
      • 9.5.2.1. Overview
      • 9.5.2.2. Financial Performance
      • 9.5.2.3. Product Benchmarking
      • 9.5.2.4. Strategic Initiatives
    • 9.5.3. Helus Pharma Inc.
      • 9.5.3.1. Overview
      • 9.5.3.2. Financial Performance
      • 9.5.3.3. Product Benchmarking
      • 9.5.3.4. Strategic Initiatives
    • 9.5.4. GH Research plc.
      • 9.5.4.1. Overview
      • 9.5.4.2. Financial Performance
      • 9.5.4.3. Product Benchmarking
      • 9.5.4.4. Strategic Initiatives
    • 9.5.5. Johnson & Johnson
      • 9.5.5.1. Overview
      • 9.5.5.2. Financial Performance
      • 9.5.5.3. Product Benchmarking
      • 9.5.5.4. Strategic Initiatives
    • 9.5.6. Eli Lilly and Company
      • 9.5.6.1. Overview
      • 9.5.6.2. Financial Performance
      • 9.5.6.3. Product Benchmarking
      • 9.5.6.4. Strategic Initiatives
    • 9.5.7. Otsuka Pharmaceutical Co., Ltd.
      • 9.5.7.1. Overview
      • 9.5.7.2. Financial Performance
      • 9.5.7.3. Product Benchmarking
      • 9.5.7.4. Strategic Initiatives
    • 9.5.8. AbbVie Inc.
      • 9.5.8.1. Overview
      • 9.5.8.2. Financial Performance
      • 9.5.8.3. Product Benchmarking
      • 9.5.8.4. Strategic Initiatives
    • 9.5.9. Incannex Healthcare Limited
      • 9.5.9.1. Overview
      • 9.5.9.2. Financial Performance
      • 9.5.9.3. Product Benchmarking
      • 9.5.9.4. Strategic Initiatives
    • 9.5.10. Optimi Health Corp.
      • 9.5.10.1. Overview
      • 9.5.10.2. Financial Performance
      • 9.5.10.3. Product Benchmarking
      • 9.5.10.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global psychedelic drugs market, by region, 2021 - 2033 (USD Million)
  • Table 4 Global psychedelic drugs market, by drug type, 2021 - 2033 (USD Million)
  • Table 5 Global psychedelic drugs market, by indication, 2021 - 2033 (USD Million)
  • Table 6 Global psychedelic drugs market, by route of administration, 2021 - 2033 (USD Million)
  • Table 7 Global psychedelic drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 8 North America psychedelic drugs market, by country, 2021 - 2033 (USD Million)
  • Table 9 North America psychedelic drugs market, by drug type, 2021 - 2033 (USD Million)
  • Table 10 North America psychedelic drugs market, by indication, 2021 - 2033 (USD Million)
  • Table 11 North America psychedelic drugs market, by route of administration, 2021 - 2033 (USD Million)
  • Table 12 North America psychedelic drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 13 U.S. psychedelic drugs market, by drug type, 2021 - 2033 (USD Million)
  • Table 14 U.S. psychedelic drugs market, by indication, 2021 - 2033 (USD Million)
  • Table 15 U.S. psychedelic drugs market, by route of administration, 2021 - 2033 (USD Million)
  • Table 16 U.S psychedelic drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 17 Canada psychedelic drugs market, by drug type, 2021 - 2033 (USD Million)
  • Table 18 Canada psychedelic drugs market, by indication, 2021 - 2033 (USD Million)
  • Table 19 Canada psychedelic drugs market, by route of administration, 2021 - 2033 (USD Million)
  • Table 20 Canada psychedelic drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 21 Mexico psychedelic drugs market, by drug type, 2021 - 2033 (USD Million)
  • Table 22 Mexico psychedelic drugs market, by indication, 2021 - 2033 (USD Million)
  • Table 23 Mexico psychedelic drugs market, by route of administration, 2021 - 2033 (USD Million)
  • Table 24 Mexico psychedelic drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 25 Europe psychedelic drugs market, by country, 2021 - 2033 (USD Million)
  • Table 26 Europe psychedelic drugs market, by drug type, 2021 - 2033 (USD Million)
  • Table 27 Europe psychedelic drugs market, by indication, 2021 - 2033 (USD Million)
  • Table 28 Europe psychedelic drugs market, by route of administration, 2021 - 2033 (USD Million)
  • Table 29 Europe psychedelic drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 30 UK psychedelic drugs market, by drug type, 2021 - 2033 (USD Million)
  • Table 31 UK psychedelic drugs market, by indication, 2021 - 2033 (USD Million)
  • Table 32 UK psychedelic drugs market, by route of administration, 2021 - 2033 (USD Million)
  • Table 33 UK psychedelic drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 34 Germany psychedelic drugs market, by drug type, 2021 - 2033 (USD Million)
  • Table 35 Germany psychedelic drugs market, by indication, 2021 - 2033 (USD Million)
  • Table 36 Germany psychedelic drugs market, by route of administration, 2021 - 2033 (USD Million)
  • Table 37 Germany psychedelic drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 38 France psychedelic drugs market, by drug type, 2021 - 2033 (USD Million)
  • Table 39 France psychedelic drugs market, by indication, 2021 - 2033 (USD Million)
  • Table 40 France psychedelic drugs market, by route of administration, 2021 - 2033 (USD Million)
  • Table 41 France psychedelic drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 42 Italy psychedelic drugs market, by drug type, 2021 - 2033 (USD Million)
  • Table 43 Italy psychedelic drugs market, by indication, 2021 - 2033 (USD Million)
  • Table 44 Italy psychedelic drugs market, by route of administration, 2021 - 2033 (USD Million)
  • Table 45 Italy psychedelic drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 46 Spain psychedelic drugs market, by drug type, 2021 - 2033 (USD Million)
  • Table 47 Spain psychedelic drugs market, by indication, 2021 - 2033 (USD Million)
  • Table 48 Spain psychedelic drugs market, by route of administration, 2021 - 2033 (USD Million)
  • Table 49 Spain psychedelic drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 50 Norway psychedelic drugs market, by drug type, 2021 - 2033 (USD Million)
  • Table 51 Norway psychedelic drugs market, by indication, 2021 - 2033 (USD Million)
  • Table 52 Norway psychedelic drugs market, by route of administration, 2021 - 2033 (USD Million)
  • Table 53 Norway psychedelic drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 54 Denmark psychedelic drugs market, by drug type, 2021 - 2033 (USD Million)
  • Table 55 Denmark psychedelic drugs market, by indication, 2021 - 2033 (USD Million)
  • Table 56 Denmark psychedelic drugs market, by route of administration, 2021 - 2033 (USD Million)
  • Table 57 Denmark psychedelic drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 58 Sweden psychedelic drugs market, by drug type, 2021 - 2033 (USD Million)
  • Table 59 Sweden psychedelic drugs market, by indication, 2021 - 2033 (USD Million)
  • Table 60 Sweden psychedelic drugs market, by route of administration, 2021 - 2033 (USD Million)
  • Table 61 Sweden psychedelic drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 62 Asia Pacific psychedelic drugs market, by country, 2021 - 2033 (USD Million)
  • Table 63 Asia Pacific psychedelic drugs market, by drug type, 2021 - 2033 (USD Million)
  • Table 64 Asia Pacific psychedelic drugs market, by indication, 2021 - 2033 (USD Million)
  • Table 65 Asia Pacific psychedelic drugs market, by route of administration, 2021 - 2033 (USD Million)
  • Table 66 Asia Pacific psychedelic drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 67 Japan psychedelic drugs market, by drug type, 2021 - 2033 (USD Million)
  • Table 68 Japan psychedelic drugs market, by indication, 2021 - 2033 (USD Million)
  • Table 69 Japan psychedelic drugs market, by route of administration, 2021 - 2033 (USD Million)
  • Table 70 Japan psychedelic drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 71 China psychedelic drugs market, by drug type, 2021 - 2033 (USD Million)
  • Table 72 China psychedelic drugs market, by indication, 2021 - 2033 (USD Million)
  • Table 73 China psychedelic drugs market, by route of administration, 2021 - 2033 (USD Million)
  • Table 74 China psychedelic drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 75 India psychedelic drugs market, by drug type, 2021 - 2033 (USD Million)
  • Table 76 India psychedelic drugs market, by indication, 2021 - 2033 (USD Million)
  • Table 77 India psychedelic drugs market, by route of administration, 2021 - 2033 (USD Million)
  • Table 78 India psychedelic drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 79 Australia psychedelic drugs market, by drug type, 2021 - 2033 (USD Million)
  • Table 80 Australia psychedelic drugs market, by indication, 2021 - 2033 (USD Million)
  • Table 81 Australia psychedelic drugs market, by route of administration, 2021 - 2033 (USD Million)
  • Table 82 Australia psychedelic drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 83 South Korea psychedelic drugs market, by drug type, 2021 - 2033 (USD Million)
  • Table 84 South Korea psychedelic drugs market, by indication, 2021 - 2033 (USD Million)
  • Table 85 South Korea psychedelic drugs market, by route of administration, 2021 - 2033 (USD Million)
  • Table 86 South Korea psychedelic drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 87 Thailand psychedelic drugs market, by drug type, 2021 - 2033 (USD Million)
  • Table 88 Thailand psychedelic drugs market, by indication, 2021 - 2033 (USD Million)
  • Table 89 Thailand psychedelic drugs market, by route of administration, 2021 - 2033 (USD Million)
  • Table 90 Thailand psychedelic drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 91 Latin America psychedelic drugs market, by country, 2021 - 2033 (USD Million)
  • Table 92 Latin America psychedelic drugs market, by drug type, 2021 - 2033 (USD Million)
  • Table 93 Latin America psychedelic drugs market, by indication, 2021 - 2033 (USD Million)
  • Table 94 Latin America psychedelic drugs market, by route of administration, 2021 - 2033 (USD Million)
  • Table 95 Latin America psychedelic drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 96 Brazil psychedelic drugs market, by drug type, 2021 - 2033 (USD Million)
  • Table 97 Brazil psychedelic drugs market, by indication, 2021 - 2033 (USD Million)
  • Table 98 Brazil psychedelic drugs market, by route of administration, 2021 - 2033 (USD Million)
  • Table 99 Brazil psychedelic drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 100 Argentina psychedelic drugs market, by drug type, 2021 - 2033 (USD Million)
  • Table 101 Argentina psychedelic drugs market, by indication, 2021 - 2033 (USD Million)
  • Table 102 Argentina psychedelic drugs market, by route of administration, 2021 - 2033 (USD Million)
  • Table 103 Argentina psychedelic drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 104 Middle East & Africa psychedelic drugs market, by country, 2021 - 2033 (USD Million)
  • Table 105 Middle East & Africa psychedelic drugs market, by drug type, 2021 - 2033 (USD Million)
  • Table 106 Middle East & Africa psychedelic drugs market, by indication, 2021 - 2033 (USD Million)
  • Table 107 Middle East & Africa psychedelic drugs market, by route of administration, 2021 - 2033 (USD Million)
  • Table 108 Middle East & Africa psychedelic drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 109 South Africa psychedelic drugs market, by drug type, 2021 - 2033 (USD Million)
  • Table 110 South Africa psychedelic drugs market, by indication, 2021 - 2033 (USD Million)
  • Table 111 South Africa psychedelic drugs market, by route of administration, 2021 - 2033 (USD Million)
  • Table 112 South Africa psychedelic drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 113 Saudi Arabia psychedelic drugs market, by drug type, 2021 - 2033 (USD Million)
  • Table 114 Saudi Arabia psychedelic drugs market, by indication, 2021 - 2033 (USD Million)
  • Table 115 Saudi Arabia psychedelic drugs market, by route of administration, 2021 - 2033 (USD Million)
  • Table 116 Saudi Arabia psychedelic drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 117 UAE psychedelic drugs market, by drug type, 2021 - 2033 (USD Million)
  • Table 118 UAE psychedelic drugs market, by indication, 2021 - 2033 (USD Million)
  • Table 119 UAE psychedelic drugs market, by route of administration, 2021 - 2033 (USD Million)
  • Table 120 UAE psychedelic drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 121 Kuwait psychedelic drugs market, by drug type, 2021 - 2033 (USD Million)
  • Table 122 Kuwait psychedelic drugs market, by indication, 2021 - 2033 (USD Million)
  • Table 123 Kuwait psychedelic drugs market, by route of administration, 2021 - 2033 (USD Million)
  • Table 124 Kuwait psychedelic drugs market, by distribution channel, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Psychedelic drugs market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Competitive landscape
  • Fig. 10 Psychedelic drugs market dynamics
  • Fig. 11 Psychedelic drugs market: Porter's five forces analysis
  • Fig. 12 Psychedelic drugs market: PESTLE analysis
  • Fig. 13 Drug Type market, 2021 - 2033 (USD Million)
  • Fig. 14 Classical psychedelics market, 2021 - 2033 (USD Million)
  • Fig. 15 Entactogens market, 2021 - 2033 (USD Million)
  • Fig. 16 Dissociatives market, 2021 - 2033 (USD Million)
  • Fig. 17 Others market, 2021 - 2033 (USD Million)
  • Fig. 18 Indication market, 2021 - 2033 (USD Million)
  • Fig. 19 Depressive disorders market, 2021 - 2033 (USD Million)
  • Fig. 20 Trauma- and stressor-related disorders market, 2021 - 2033 (USD Million)
  • Fig. 21 Anxiety disorders market, 2021 - 2033 (USD Million)
  • Fig. 22 Substance use disorders market, 2021 - 2033 (USD Million)
  • Fig. 23 Obsessive-compulsive and related disorders market, 2021 - 2033 (USD Million)
  • Fig. 24 End-of-life psychological distress market, 2021 - 2033 (USD Million)
  • Fig. 25 Others market, 2021 - 2033 (USD Million)
  • Fig. 26 Route of administration market, 2021 - 2033 (USD Million)
  • Fig. 27 Oral market, 2021 - 2033 (USD Million)
  • Fig. 28 Intranasal market, 2021 - 2033 (USD Million)
  • Fig. 29 Parenteral market, 2021 - 2033 (USD Million)
  • Fig. 30 Others market, 2021 - 2033 (USD Million)
  • Fig. 31 Distribution channel market, 2021 - 2033 (USD Million)
  • Fig. 32 Hospital pharmacies market, 2021 - 2033 (USD Million)
  • Fig. 33 Specialty pharmacies market, 2021 - 2033 (USD Million)
  • Fig. 34 Retail pharmacies market, 2021 - 2033 (USD Million)
  • Fig. 35 Others market, 2021 - 2033 (USD Million)
  • Fig. 36 Psychedelic drugs market revenue, by region
  • Fig. 37 Regional marketplace: Key takeaways
  • Fig. 38 North America psychedelic drugs market, 2021 - 2033 (USD Million)
  • Fig. 39 U.S. country dynamics
  • Fig. 40 U.S. psychedelic drugs market, 2021 - 2033 (USD Million)
  • Fig. 41 Canada country dynamics
  • Fig. 42 Canada psychedelic drugs market, 2021 - 2033 (USD Million)
  • Fig. 43 Mexico country dynamics
  • Fig. 44 Mexico psychedelic drugs market, 2021 - 2033 (USD Million)
  • Fig. 45 Europe psychedelic drugs market, 2021 - 2033 (USD Million)
  • Fig. 46 UK country dynamics
  • Fig. 47 UK psychedelic drugs market, 2021 - 2033 (USD Million)
  • Fig. 48 Germany country dynamics
  • Fig. 49 Germany psychedelic drugs market, 2021 - 2033 (USD Million)
  • Fig. 50 France country dynamics
  • Fig. 51 France psychedelic drugs market, 2021 - 2033 (USD Million)
  • Fig. 52 Italy country dynamics
  • Fig. 53 Italy psychedelic drugs market, 2021 - 2033 (USD Million)
  • Fig. 54 Spain country dynamics
  • Fig. 55 Spain psychedelic drugs market, 2021 - 2033 (USD Million)
  • Fig. 56 Norway country dynamics
  • Fig. 57 Norway psychedelic drugs market, 2021 - 2033 (USD Million)
  • Fig. 58 Sweden country dynamics
  • Fig. 59 Sweden psychedelic drugs market, 2021 - 2033 (USD Million)
  • Fig. 60 Denmark country dynamics
  • Fig. 61 Denmark psychedelic drugs market, 2021 - 2033 (USD Million)
  • Fig. 62 Asia Pacific psychedelic drugs market, 2021 - 2033 (USD Million)
  • Fig. 63 Japan country dynamics
  • Fig. 64 Japan psychedelic drugs market, 2021 - 2033 (USD Million)
  • Fig. 65 China country dynamics
  • Fig. 66 China psychedelic drugs market, 2021 - 2033 (USD Million)
  • Fig. 67 India country dynamics
  • Fig. 68 India psychedelic drugs market, 2021 - 2033 (USD Million)
  • Fig. 69 Australia country dynamics
  • Fig. 70 Australia psychedelic drugs market, 2021 - 2033 (USD Million)
  • Fig. 71 South Korea country dynamics
  • Fig. 72 South Korea psychedelic drugs market, 2021 - 2033 (USD Million)
  • Fig. 73 Thailand country dynamics
  • Fig. 74 Thailand psychedelic drugs market, 2021 - 2033 (USD Million)
  • Fig. 75 Latin America psychedelic drugs market, 2021 - 2033 (USD Million)
  • Fig. 76 Brazil country dynamics
  • Fig. 77 Brazil psychedelic drugs market, 2021 - 2033 (USD Million)
  • Fig. 78 Argentina country dynamics
  • Fig. 79 Argentina psychedelic drugs market, 2021 - 2033 (USD Million)
  • Fig. 80 MEA psychedelic drugs market, 2021 - 2033 (USD Million)
  • Fig. 81 South Africa country dynamics
  • Fig. 82 South Africa psychedelic drugs market, 2021 - 2033 (USD Million)
  • Fig. 83 Saudi Arabia country dynamics
  • Fig. 84 Saudi Arabia psychedelic drugs market, 2021 - 2033 (USD Million)
  • Fig. 85 UAE country dynamics
  • Fig. 86 UAE psychedelic drugs market, 2021 - 2033 (USD Million)
  • Fig. 87 Kuwait country dynamics
  • Fig. 88 Kuwait psychedelic drugs market, 2021 - 2033 (USD Million)
  • Fig. 89 Company categorization
  • Fig. 90 Company market position analysis
  • Fig. 91 Strategic framework